|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 233.80 USD | -6.09% |
|
-4.30% | +28.01% |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 12,031 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 30.67% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 11,921 | 11,637 | 11,060 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 31.4% | -2.37% | -4.96% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -115x | 40.8x | 16.2x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 12,383x | 40.6x | 14.3x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.6x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 12.3x | 7.53x | 5.25x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 12.1x | 7.28x | 4.83x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -87.2x | 49.3x | 20.8x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -123x | 33.3x | 12x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -197x | 31.9x | 16.3x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -0.51% | 3.13% | 6.13% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.029 | 5.736 | 14.41 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 981.3 | 1,599 | 2,292 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -136.7 | 236.2 | 531.6 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -97.21 | 349.5 | 920 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -105.5 | 317.4 | 806.1 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -110.7 | -393.8 | -970.8 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 233.80 | 233.80 | 233.80 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 51,460 | - | - |
| Announcement Date | 3/1/22 | 2/27/23 | 2/20/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -125.28x | 12.87x | -114.19x | -.--% | 12.81B | |
| 17.29x | 3.79x | 10.17x | 0.58% | 67.96B | |
| 27.02x | 5.55x | 16.28x | 0.59% | 54.4B | |
| -46.91x | 3.29x | 9.71x | 3.27% | 41.74B | |
| 32.87x | 11.12x | 21.25x | -.--% | 40.63B | |
| -8.83x | 12.88x | -7.91x | -.--% | 30.38B | |
| 30.31x | 3.47x | 10.96x | -.--% | 29.37B | |
| 17.2x | 3.3x | 10.01x | -.--% | 23.68B | |
| 57.92x | 6.05x | 41.38x | -.--% | 19.15B | |
| -41.11x | 19.11x | -58.05x | -.--% | 17.68B | |
| Average | -3.95x | 8.14x | -6.04x | 0.44% | 33.78B | |
| Weighted average by Cap. | 5.42x | 6.92x | 4.35x | 0.62% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
